+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-31Number of Pages: 171

Prostate Cancer Therapeutics Market (Therapy Type - Hormone Therapy {Luteinizing Hormone-Releasing Hormone Analogs, Luteinizing Hormone-Releasing Hormone Antagonists, and Antiandrogens}, Chemotherapy {Systemic Chemotherapy and Regional Chemotherapy}, Biologic Therapy, and Targeted Therapy); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Prostate Cancer Therapeutics Market: Snapshot

Prostate cancer is a serious health issue among men and has a large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is the fourth-most common cancer diagnosed globally. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual.

Approximately 75% of prostate cancers are developed sporadically, in which genetic changes occur after birth. Although, the real cause of prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight, and past history of certain cancers. The global prostate cancer therapeutics market was valued at US$8.78 bn in 2015. Rising at a CAGR of 8.1% between 2016 and 2024, the market is expected to reach US$17.53 bn by the end of 2025. The overall market is segmented on the basis of therapy type, and distribution channel segments. global prostate cancer therapeutics market

Hormone Therapy to Remain Dominant Segment Based on Therapy Type

Based on therapy type, the global prostate cancer therapeutics market is segmented into hormone therapy, chemotherapy, biologic therapy, and targeted therapy. Of these, the hormone therapy segment dominated global prostate cancer therapeutics market with a share of 82.7% in 2015. Hormone therapy offers excellent efficacy in castration resistant prostate cancer patients, which is a chief factor fuelling its demand in the treatment of prostate cancer patients. The dominance of the segment is thus forecast to remain unaffected through the forecast period.

Besides this, the targeted therapy segment is anticipated to gain market share during forecast period due to expected new product launches in this segment. The biologic therapy segment is expected to have a moderate market share and is likely to expand with a high CAGR during the forecast period due to introduction of novel therapy products in prostate cancer therapeutics market and increase in prevalence of prostate cancer globally.

Based on distribution channel, the global prostate cancer therapeutics market is segmented into hospital pharmacy, online sales, retail pharmacy, and others. Of these, the hospital pharmacy segment emerged dominant in 2015. The segment is gaining momentum on account of the rising incidence of prostate cancer around the world and advancements in diagnosis techniques. As an increasing number of patients seek medical care in hospitals, the hospital pharmacy segment will witness accelerated pace of gains in response. In addition, the online sales segment is forecast to witness significant growth over the forecast period. This segment will gain from the rising use of mobile based applications for placing online orders for medicines.

North America and Europe Cumulatively Hold Leading Market Share

Regionally, North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa constitute the key segments in the global prostate cancer therapeutics market. Among these, North America and Europe cumulatively held the leading market share in 2015. This trend is likely to continue through the forecast period. While in 2015, North America emerged dominant holding a marginally higher share of 39.8% as compared to Europe, in the coming years the table is expected to turn in favor of Europe.

The rising diseased population and a sophisticated healthcare infrastructure will support growth of the prostate cancer therapeutics market in North America and Europe. Besides this, Asia Pacific and Latin America are expected to emerge as promising market owing to the increasing awareness about prostate cancer and the available treatment and diagnosis options. The rising healthcare spending will also support the market’s expansion in Asia Pacific and Latin America.

Pfizer, Inc. dominated the global prostate cancer therapeutics market in 2015. Major factors attributed to its dominance are acquisition of leading brand, and widespread market presence. Other players in the global prostate cancer therapeutics market include Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., Dendreon Corporation (Sanpower Group Co. Ltd.) and others

Chapter 1. Preface 
1.1. Report Scope and Market Segmentation 
1.2. Research Highlights

Chapter 2. Assumptions and Research Methodology 
2.1. Assumptions
2.2. Research Methodology

Chapter 3. Executive Summary 
3.1. Global Prostate Cancer Therapeutics Market : Snapshot, 2015
3.2. Global Prostate Cancer Therapeutics Market : Opportunity Map

Chapter 4. Market Overview
4.1. Product Overview
4.2. Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, 2014–2024 
4.3. Global Prostate Cancer Therapeutics Market Outlook
4.4. Global Prostate Cancer Therapeutics Market : Key Industry Events
4.5. Global Prostate Cancer Therapeutics Market : Porter's Analysis
4.6. Global Prostate Cancer Therapeutics Market : Pipeline Analysis
4.7. Key Product Opportunities

Chapter 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
       5.2.1. Increasing prevalence of prostate cancer 
       5.2.2. Launch of promising emerging therapies
       5.2.3. Innovation in the development of new drugs and therapeutic biological products
       5.2.4. High growth in hormone-refractory prostate cancer drug due to lesser side effects
5.3. Restrains
       5.3.1. High cost of treatment
       5.3.2. Reluctance toward adoption of premium treatments
5.4. Opportunity Analysis
5.5. Opportunities
       5.5.1. Large undiagnosed patient population
       5.5.2. Rise in funding from both public and private sector in the field of drug development
5.6. Key Trends 
       5.6.1. Increasing application of biotechnology in anticancer drugs development
       5.6.2. New drugs entering the market with higher costs 
       5.6.3. Oral drugs account for a large share of the oncology drugs market

Chapter 6. Prostate Cancer Therapeutics Market Analysis, by Product Type
6.1. Prostate Cancer Therapeutics Market Analysis, by Therapy
6.2. Key Findings
6.3. Introduction
6.4. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Therapy
6.5. Prostate Cancer Therapeutics Market Analysis, by Therapy 
       6.5.1. Hormone Therapy
       6.5.2. Luteinizing Hormone-Releasing Hormone Analogs
       6.5.3. Luteinizing Hormone-Releasing Hormone Antagonists
       6.5.4. Antiandrogens
6.6. Chemotherapy
       6.6.1. Systemic Chemotherapy
       6.6.2. Regional Chemotherapy
6.7. Biologic Therapy
6.8. Targeted Therapy
6.9. Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016-2024
6.10. Key Trends

Chapter 7. Prostate Cancer Therapeutics Market Analysis, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.3. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Distribution Channel
7.4. Prostate Cancer Therapeutics Market Analysis, by Distribution Channel
       7.4.1. Hospital Pharmacy 
       7.4.2. Retail Pharmacy 
       7.4.3. Online Sales 
       7.4.4. Others
7.5. Market Attractiveness Analysis, by Distribution Channel 
7.6. Key Trends

Chapter 8. Prostate Cancer Therapeutics Market Analysis, by Region
8.1. Global Prostate Cancer Therapeutics Market Snapshot, by Country
8.2. Global Prostate Cancer Therapeutics Market Value Share Analysis, by Region
8.3. Prostate Cancer Therapeutics Market Forecast, by Region
8.4. Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region, 2016-2024 

Chapter 9. North America Prostate Cancer Therapeutics Market Analysis
9.1. Key Findings
9.2. North America Prostate Cancer Therapeutics Market Overview
9.3. North America Market Value Share Analysis, by Therapy
9.4. North America Market Forecast, by Therapy
       9.4.1. Hormone Therapy
                9.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
                9.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
                9.4.1.3. Antiandrogens
       9.4.2. Chemotherapy
                9.4.2.1. Systemic Chemotherapy
                9.4.2.2. Regional Chemotherapy
       9.4.3. Biologic Therapy
       9.4.4. Targeted Therapy
9.5. North America Market Value Share Analysis, by Distribution Channel
9.6. North America Market Forecast, by Distribution Channel
       9.6.1. Hospital Pharmacy
       9.6.2. Retail Pharmacy
       9.6.3. Online Sales
       9.6.4. Others
9.7. Market Analysis, by Country
9.8. Market Value Share Analysis, by Country
9.9. Market Size (US$ Mn) Forecast, by Country, 2016–2024
       9.9.1. U.S.
       9.9.2. Canada
9.10. Market Attractiveness Analysis
       9.10.1. By Product 
       9.10.2. By Distribution Channel
       9.10.3. By Country
9.11. Market Trends

Chapter 10. Europe Prostate Cancer Therapeutics Market Analysis
10.1. Key Findings
10.2. Europe Prostate Cancer Therapeutics Market Overview
10.3. Europe Market Value Share Analysis, by Therapy
10.4. Europe Market Forecast, by Therapy
       10.4.1. Hormone Therapy
                10.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
                10.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
                10.4.1.3. Antiandrogens
       10.4.2. Chemotherapy
                10.4.2.1. Systemic Chemotherapy
                10.4.2.2. Regional Chemotherapy
       10.4.3. Biologic Therapy
       10.4.4. Targeted Therapy
10.5. Europe Market Value Share Analysis, by Distribution Channel
10.6. Europe Market Forecast, by Distribution Channel
       10.6.1. Hospital Pharmacy
       10.6.2. Retail Pharmacy
       10.6.3. Online Sales
       10.6.4. Others
10.7. Market Analysis, by Country
10.8. Market Value Share Analysis, by Country
10.9. Market Size (US$ Mn) Forecast, by Country, 2016–2024
       10.9.1. U.K.
       10.9.2. Germany
       10.9.3. Italy
       10.9.4. France
       10.9.5. Spain
       10.9.6. Russia
       10.9.7. Rest of Europe
10.10. Market Attractiveness Analysis
       10.10.1. By Product 
       10.10.2. By Distribution Channel
       10.10.3. By Country
10.11. Market Trends

Chapter 11. Asia Pacific Prostate Cancer Therapeutics Market Analysis
11.1. Key Findings
11.2. Asia Pacific Prostate Cancer Therapeutics Market Overview
11.3. Asia Pacific Market Value Share Analysis, by Therapy
11.4. Asia Pacific Market Forecast, by Therapy
       11.4.1. Hormone Therapy
                11.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
                11.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
                11.4.1.3. Antiandrogens
       11.4.2. Chemotherapy
11.4.2.1. Systemic Chemotherapy
11.4.2.2. Regional Chemotherapy
       11.4.3. Biologic Therapy
       11.4.4. Targeted Therapy
11.5. Asia Pacific Market Value Share Analysis, by Distribution Channel
11.6. Asia Pacific Market Forecast, by Distribution Channel
       11.6.1. Hospital Pharmacy
       11.6.2. Retail Pharmacy
       11.6.3. Online Sales
       11.6.4. Others
11.7. Market Analysis, by Country
11.8. Market Value Share Analysis, by Country
11.9. Market Size (US$ Mn) Forecast, by Country, 2016–2024
       11.9.1. China
       11.9.2. Japan
       11.9.3. India
       11.9.4. Australia & New Zealand
       11.9.5. Rest of Asia Pacific
11.10. Market Attractiveness Analysis
       11.10.1. By Product 
       11.10.2. By Distribution Channel
       11.10.3. By Country
11.11. Market Trends

Chapter 12. Latin America Prostate Cancer Therapeutics Market Analysis
12.1. Key Findings
12.2. Latin America Prostate Cancer Therapeutics Market Overview
12.3. Latin America Market Value Share Analysis, by Therapy
12.4. Latin America Market Forecast, by Therapy
       12.4.1. Hormone Therapy
                12.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
                12.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
                12.4.1.3. Antiandrogens       
       12.4.2. Chemotherapy
                12.4.2.1. Systemic Chemotherapy
                12.4.2.2. Regional Chemotherapy
       12.4.3. Biologic Therapy
       12.4.4. Targeted Therapy
12.5. Latin America Market Value Share Analysis, by Distribution Channel
12.6. Latin America Market Forecast, by Distribution Channel
       12.6.1. Hospital Pharmacy
       12.6.2. Retail Pharmacy
       12.6.3. Online Sales
       12.6.4. Others
12.7. Market Analysis, by Country
12.8. Market Value Share Analysis, by Country
12.9. Market Size (US$ Mn) Forecast, by Country, 2016–2024
       12.9.1. Brazil
       12.9.2. Mexico
       12.9.3. Rest of Latin America
12.10. Market Attractiveness Analysis
       12.10.1. By Product 
       12.10.2. By Distribution Channel
       12.10.3. By Country
12.11. Market Trends

Chapter 13. Middle East & Africa Prostate Cancer Therapeutics Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Prostate Cancer Therapeutics Market Overview
13.3. Middle East & Africa Market Value Share Analysis, by Therapy
13.4. Middle East & Africa Market Forecast, by Therapy
       13.4.1. Hormone Therapy
                13.4.1.1. Luteinizing Hormone-Releasing Hormone Analogs
                13.4.1.2. Luteinizing Hormone-Releasing Hormone Antagonists
                13.4.1.3. Antiandrogens
       13.4.2. Chemotherapy
                13.4.2.1. Systemic Chemotherapy
                13.4.2.2. Regional Chemotherapy
       13.4.3. Biologic Therapy
       13.4.4. Targeted Therapy
13.5. Middle East & Africa Market Value Share Analysis, by Distribution Channel
13.6. Middle East & Africa Market Forecast, by Distribution Channel
       13.6.1. Hospital Pharmacy
       13.6.2. Retail Pharmacy
       13.6.3. Online Sales 
       13.6.4. Others
13.7. Market Analysis, by Country
13.8. Market Value Share Analysis, by Country
13.9. Market Size (US$ Mn) Forecast, by Country, 2016–2024
       13.9.1. Brazil
       13.9.2. Mexico
       13.9.3. Rest of Latin America
13.10. Market Attractiveness Analysis
       13.10.1. By Product 
       13.10.2. By Distribution Channel
       13.10.3. By Country
13.11. Market Trends

Chapter 14. Company Profiles
14.1. Prostate Cancer Therapeutics Market Share Analysis, by Company, 2016 (Estimated)
14.2. Competition Matrix
14.3. Company Profiles
       14.3.1. Amgen, Inc.
                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.1.2. Financial Overview
                14.3.1.3. Product Portfolio
                14.3.1.4. SWOT Analysis
                14.3.1.5. Strategic Overview
       14.3.2. Johnson & Johnson (Janssen Biotech, Inc.)
                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.2.2. Financial Overview
                14.3.2.3. Product Portfolio
                14.3.2.4. SWOT Analysis
                14.3.2.5. Strategic Overview
       14.3.3. Pfizer, Inc. 
                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.3.2. Financial Overview
                14.3.3.3. Product Portfolio
                14.3.3.4. SWOT Analysis
                14.3.3.5. Strategic Overview
       14.3.4. AstraZeneca
                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.4.2. Financial Overview
                14.3.4.3. Product Portfolio
                14.3.4.4. SWOT Analysis
                14.3.4.5. Strategic Overview
       14.3.5. AbbVie, Inc.
                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.5.2. Financial Overview
                14.3.5.3. Product Portfolio
                14.3.5.4. SWOT Analysis
                14.3.5.5. Strategic Overview
       14.3.6. Bayer AG 
                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.6.2. Financial Overview
                14.3.6.3. Product Portfolio
                14.3.6.4. SWOT Analysis
                14.3.6.5. Strategic Overview
       14.3.7. Ipsen Group
                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.7.2. Financial Overview
                14.3.7.3. Product Portfolio
                14.3.7.4. SWOT Analysis
                14.3.7.5. Strategic Overview
       14.3.8. Sanofi
                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.8.2. Financial Overview
                14.3.8.3. Product Portfolio
                14.3.8.4. SWOT Analysis
                14.3.8.5. Strategic Overview
       14.3.9. Endo Pharmaceuticals, Inc. 
                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                14.3.9.2. Financial Overview
                14.3.9.3. Product Portfolio
                14.3.9.4. SWOT Analysis
                14.3.9.5. Strategic Overview
       14.3.10. Dendreon Corporation (Sanpower Group Co. Ltd.) 
                14.3.10.1. Company Overview (HQ, Business Segments,)
                14.3.10.2. Product Portfolio
                14.3.10.3. SWOT Analysis
                14.3.10.4. Strategic Overview

List of Figures

Figure 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 2: Global Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 3: Global Hormone Therapy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 4: Global Chemotherapy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 5: Global Biologic Therapy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 6: Global Targeted Therapy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 7: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016–2024
Figure 8: Global Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 9: Global Hospital Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Retail Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Online Sales Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 13: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 14: Global Prostate Cancer Therapeutics Market Value Share, by Region, 2016 and 2024
Figure 15: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region, 2016–2024
Figure 16: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 17: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2016–2024
Figure 18: North America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 19: North America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 20: North America Prostate Cancer Therapeutics Market Value Share, by Country, 2016 and 2024
Figure 21: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016–2024
Figure 22: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 23: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 24: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2016–2024
Figure 25: Europe Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 26: Europe Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 27: Europe Prostate Cancer Therapeutics Market Value Share, by Country, 2016 and 2024
Figure 28: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016–2024
Figure 29: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 30: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 31: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2016-2024
Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Country, 2016 and 2024
Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016-2024
Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016-2024
Figure 37: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 38: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2016-2024
Figure 39: Latin America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 40: Latin America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 41: Latin America Prostate Cancer Therapeutics Market Value Share, by Country, 2016 and 2024
Figure 42: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016-2024
Figure 43: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016-2024
Figure 44: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 45: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2016-2024
Figure 46: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Therapy, 2016 and 2024
Figure 47: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2016 and 2024
Figure 48: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Country, 2016 and 2024
Figure 49: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2016-2024
Figure 50: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2016-2024
Figure 51: Global Prostate Cancer Therapeutics Market Share Analysis, by Company, 2016 (Estimated)

List of Tables

Table 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 2: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 3: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2014–2024
Table 4: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 5: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 6: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 7: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 8: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2014–2024
Table 9: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 10: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 11: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 12: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 13: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2014–2024
Table 14: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 15: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 16: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 17: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 18: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2014–2024
Table 19: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 20: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 21: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 22: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 23: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2014–2024
Table 24: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 25: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 26: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2014–2024
Table 27: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2014–2024
Table 28: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy (Therapy), 2014–2024
Table 29: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 30: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

Global Prostate Cancer Therapeutics Market: Overview

This report on the prostate cancer therapeutics market analyzes the current and future scenario of the global market. Increasing prevalence of prostate cancer, launch of promising emerging therapies, as well as innovation in the development of new drugs & therapeutic biological products, and high growth in hormone-refractory prostate cancer drug due to lesser side effects are some of the drivers expected to drive the global prostate cancer therapeutics market during the forecast period.

The global prostate cancer therapeutics market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the country’s market with respect to the segments based on therapy type, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global prostate cancer therapeutics market.

Global Prostate Cancer Therapeutics Market: Key Segments

Based on therapy type, the market has been segmented into hormone therapy, chemotherapy, biologic therapy and targeted therapy. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference from oncologists for treating the prostate cancer with various drug classes. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on distribution channels, the global prostate cancer therapeutics market has been segmented into hospital pharmacy, retail pharmacy, online sales and others. The market segments have been extensively analyzed based on increase in demand for disease treatment among prostate cancer patients. Increased patient hospitalization for the treatment of prostate cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Global Prostate Cancer Therapeutics Market: Regional Outlook

Geographically, the global prostate cancer therapeutics market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Companies Mentioned in Report

The report also profiles major players in the global prostate cancer therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include players in the global prostate cancer therapeutics market are Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), Pfizer, Inc., AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., Dendreon Corporation (Sanpower Group Co. Ltd.) and others.

The Global Prostate Cancer Therapeutics Market is segmented as given below:

Global Prostate Cancer Therapeutics Market, by Therapy

  • Hormone Therapy
    • Luteinizing Hormone-Releasing Hormone Analogs
    • Luteinizing Hormone-Releasing Hormone Antagonists
    • Antiandrogens
  • Chemotherapy
    • Systemic Chemotherapy
    • Regional Chemotherapy
  • Biologic Therapy
  • Targeted Therapy

Global Prostate Cancer Therapeutics Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Others

Global Prostate Cancer Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East & Africa


 
 
Back To Top